Bioceres Crop Solutions (BIOX) Earnings Analysis
Bioceres Crop Solutions (BIOX) next reports earnings on 2026-09-08, consensus EPS -0.06 USD. Last quarter (2026-05-11) it missed with EPS -0.16 USD vs -0.05 USD est (-220%). It has beaten estimates in 1/7 recent quarters (14%). Trailing P/E -0.09.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BIOX next report earnings?
| Next earnings date | 2026-09-08 |
|---|---|
| Consensus EPS estimate | -0.06 USD |
| Revenue estimate | 0.08B |
BIOX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.16 USD | -0.05 USD | -220% | Miss |
| 2026-03-13 | -0.08 USD | 0.07 USD | -214.3% | Miss |
| 2025-11-13 | -0.12 USD | -0.04 USD | -200% | Miss |
| 2025-09-09 | -0.7 USD | 0.1 USD | -800% | Miss |
| 2025-05-21 | -0.02 USD | -0.1 USD | +80% | Beat |
| 2024-11-11 | -0.09 USD | -0.01 USD | -800% | Miss |
| 2024-09-09 | -0.03 USD | 0.2 USD | -115% | Miss |
Beat rate: 1/7 (14%) over reported quarters with consensus data.
BIOX valuation and analyst view
| Trailing P/E | -0.09 |
|---|---|
| Trailing EPS | -3.88764 USD |
| Price / book | 0.32 |
| Dividend yield | 0.00% |
| Market cap | 0.02B |
| Analyst consensus | Buy (4 buy / 1 hold / 0 sell) |
| Avg price target | 3.63 USD |
Related research pages
Frequently asked questions
When is Bioceres Crop Solutions (BIOX)'s next earnings date?
Bioceres Crop Solutions is next scheduled to report on 2026-09-08, with a consensus EPS estimate of -0.06 USD and revenue estimate of 0.08B.
Did BIOX beat earnings last quarter?
In its 2026-05-11 report, BIOX posted EPS of -0.16 USD versus a -0.05 USD estimate — a miss of 220%.
What is BIOX's earnings track record?
Over the last 7 reported quarters with consensus data, BIOX beat estimates 1 times (14%).
What is BIOX's current P/E ratio and EPS?
BIOX trades at a trailing P/E of -0.09 on trailing EPS of -3.887643238993711 USD.
What do analysts rate BIOX?
Analyst consensus is "Buy" across 5 ratings (0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 3.63 USD.